title: Gene Therapies for Neovascular Age-Related Macular Degeneration.
abstract: Pathological neovascularization is a key component of the neovascular form (also known as the wet form) of age-related macular degeneration (AMD) and proliferative diabetic retinopathy. Several preclinical studies have shown that antiangiogenesis strategies are effective for treating neovascular AMD in animal models. Vascular endothelial growth factor (VEGF) is one of the main inducers of ocular neovascularization, and several clinical trials have shown the benefits of neutralizing VEGF in patients with neovascular AMD or diabetic macular edema. In this review, we summarize several preclinical and early-stage clinical trials with intraocular gene therapies, which have the potential to reduce or eliminate the repeated intravitreal injections that are currently required for the treatment of neovascular AMD.
authors.affiliation: Gene Therapy, Sanofi-Genzyme R&D Center, Framingham, Massachusetts 01701.
authors.forename: Peter
authors.initials: P
authors.lastname: Pechan
authors.affiliation: Gene Therapy, Sanofi-Genzyme R&D Center, Framingham, Massachusetts 01701.
authors.forename: Samuel
authors.initials: S
authors.lastname: Wadsworth
authors.affiliation: Gene Therapy, Sanofi-Genzyme R&D Center, Framingham, Massachusetts 01701.
authors.forename: Abraham
authors.initials: A
authors.lastname: Scaria
mesh_terms: D000818:Animals; D015316:Genetic Therapy; D006801:Humans; D008252:Macaca fascicularis; D008268:Macular Degeneration / Q000628:therapy*; D051379:Mice; D023421:Models, Animal; D016032:Randomized Controlled Trials as Topic; D042461:Vascular Endothelial Growth Factor A / Q000235:genetics*
chemical_list: C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A